Application of liposomal technologies for delivery of platinum analogs in oncology

Demin Liu, Chunbai He, Andrew Z. Wang, Wenbin Lin

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations

Abstract

Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research.

Original languageEnglish (US)
Pages (from-to)3309-3319
Number of pages11
JournalInternational Journal of Nanomedicine
Volume8
DOIs
StatePublished - Aug 23 2013
Externally publishedYes

Keywords

  • Cancer
  • Drug delivery
  • Liposome
  • Platinum analog

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Application of liposomal technologies for delivery of platinum analogs in oncology'. Together they form a unique fingerprint.

Cite this